Table 3.
Baseline characteristics of the retrospective cohort of confirmed COVID-19 cases
| Unvaccinated |
BNT162b2 |
CoronaVac |
p-value (Chi-Squared Test of Independence) |
|||
|---|---|---|---|---|---|---|
|
‘Late’ (Fully Vaccinated in July to August) |
‘Early’ (Fully Vaccinated in April to June) |
‘Late’ (Fully Vaccinated in July to August) |
‘Early’ (Fully Vaccinated in April to June) |
|||
| Participants | 62,506 | 30,088 | 21,906 | 104,746 | 6,052 | |
| Admitted to ICU | 1,238 (2.0%) | 101 (0.3%) | 91 (0.4%) | 830 (0.8%) | 110 (1.8%) | <0.001 |
| Death | 2,550 (4.1%) | 175 (0.6%) | 98 (0.4%) | 762 (0.7%) | 85 (1.4%) | <0.001 |
| Age Groups | <0.001 | |||||
| 18–39 | 39,846 (63.7%) | 12,598 (41.9%) | 11,784 (53.8%) | 52,174 (49.8%) | 2,197 (36.3%) | |
| 40–59 | 14,998 (24%) | 9,440 (31.4%) | 6,616 (30.2%) | 34,904 (33.3%) | 1,771 (29.3%) | |
| ≥60 | 7,662 (12.3%) | 8,050 (26.8%) | 3,506 (16%) | 17,668 (16.9%) | 2,084 (34.4%) | |
| Nationality | <0.001 | |||||
| Malaysian | 45,519 (72.8%) | 29,596 (98.4%) | 21,872 (99.8%) | 101,669 (97.1%) | 6,027 (99.6%) | |
| Non-Malaysian | 16,987 (27.2%) | 492 (1.6%) | 34 (0.2%) | 3077 (2.9%) | 25 (0.4%) | |
| Sex | <0.001 | |||||
| Male | 37,921 (60.7%) | 14,255 (47.4%) | 11,315 (51.7%) | 53,977 (51.5%) | 3,369 (55.7%) | |
| Female | 24,585 (39.3%) | 15,833 (52.6%) | 10,591 (48.3%) | 50,769 (48.5%) | 2,683 (44.3%) | |
| Presence of Comorbidities | <0.001 | |||||
| Yes | 19,315 (30.9%) | 6,618 (22.0%) | 4,618 (21.1%) | 11,310 (10.8%) | 1,223 (20.2%) | |
| No | 43,191 (69.1%) | 23,470 (78.0%) | 17,288 (78.9%) | 93,436 (89.2%) | 4,829 (79.8%) | |
| Frontliner Status | <0.001 | |||||
| General Population | 62,318 (99.7%) | 29,411 (97.7%) | 14,764 (67.4%) | 103,836 (99.1%) | 5,546 (91.6%) | |
| Public Healthcare | 83 (0.1%) | 234 (0.8%) | 5,169 (23.6%) | 40 (0.0%) | 68 (1.1%) | |
| Private Healthcare | 105 (0.2%) | 443 (1.5%) | 1,973 (9.0%) | 870 (0.8%) | 438 (7.2%) | |
| Baseline Number of Times Flagged as ‘Contact’ | <0.001 | |||||
| 0 | 59,152 (94.6%) | 25,775 (85.7%) | 18,038 (82.3%) | 87,255 (83.3%) | 5,286 (87.3%) | |
| 1 | 2,490 (4.0%) | 3,257 (10.8%) | 2,919 (13.3%) | 12,803 (12.2%) | 578 (9.6%) | |
| 2–4 | 781 (1.2%) | 1,001 (3.3%) | 903 (4.1%) | 4,359 (4.2%) | 173 (2.9%) | |
| 5–9 | 73 (0.1%) | 53 (0.2%) | 45 (0.2%) | 296 (0.3%) | 15 (0.2%) | |
| ≥10 | 10 (0.0%) | 2 (0.0%) | 1 (0.0%) | 33 (0.0%) | 0 (0.0%) | |
| Baseline Number of Supervised Tests Taken | <0.001 | |||||
| 0 | 48,385 (77.4%) | 21,581 (71.7%) | 13,549 (61.9%) | 68,853 (65.7%) | 4,181 (69.1%) | |
| 1 | 8,910 (14.3%) | 5,228 (17.4%) | 4,491 (20.5%) | 20,719 (19.8%) | 1,113 (18.4%) | |
| 2–4 | 4,781 (7.6%) | 2,987 (9.9%) | 3,615 (16.5%) | 13,706 (13.1%) | 710 (11.7%) | |
| 5–9 | 417 (0.7%) | 252 (0.8%) | 237 (1.1%) | 1,305 (1.2%) | 43 (0.7%) | |
| ≥10 | 13 (0.0%) | 40 (0.1%) | 14 (0.1%) | 163 (0.2%) | 5 (0.1%) | |
Abbreviations: COVID-19, coronavirus disease; ICU, intensive care unit; VE, vaccine effectiveness; BNT162b2, Pfizer-BioNTech; CoronaVac, Sinovac.
Breakdown by states of residence have been omitted for brevity.
Percentages in parentheses are by vaccination type and timing.
The ‘Late’ group are individuals vaccinated in July to August 2021 (1 to 2 months after vaccination during the outcomes observation period in September 2021), ‘Early’ group are individuals vaccinated in April to June 2021 (3 to 5 months after vaccination).